Management of inflammatory bowel disease (IBD) has always been a challenge for physicians. Current treatment protocols may cause numerous adverse effects. Selenium is known for its putative antiinflammatory properties. Selenium is needed for the biosynthesis of enzymatically active selenoproteins, which contribute to antioxidative defense, and effective function of immune systems. Several studies have shown that patients with IBD have a lower selenium level compared to healthy subjects. Hence, experimental studies mimicking ulcerative colitis and Crohn's disease investigated the effect of selenium supplementation on IBD. Previous studies indicated the following: 1) Selenoproteins can curb the inflammatory response and attenuate oxidative stress. This antiinflammatory property caused remission in animal models of colitis. 2) Selenium supports protective gut microbiota, which indirectly improves management of IBD. 3) Selenium may block some of the predominant tumorigenesis pathways proposed in colitis-associated colorectal cancer. 4) Selenium supplementation showed promising results in preliminary clinical studies, particularly in patients with selenium deficiency. While selenium supplementation seems to be beneficial for IBD, clinical studies have remained too preliminary in this regard. Randomized clinical trials are needed to measure the short-term and long-term effects of selenium on both active and quiescent IBD, particularly in patients with IBD who have documented selenium deficiency.

炎症性肠病（IBD）的治疗一直是医师的挑战。当前的治疗方案可能引起许多不良影响。硒以其推定的抗炎特性而闻名。酶活性硒蛋白的生物合成需要硒，硒有助于抗氧化防御和免疫系统的有效功能。几项研究表明，与健康受试者相比，IBD患者的硒水平较低。因此，模拟溃疡性结肠炎和克罗恩氏病的实验研究研究了补充硒对IBD的影响。先前的研究表明：1）硒蛋白可以抑制炎症反应并减轻氧化应激。这种抗炎特性导致结肠炎的动物模型缓解。2）硒可保护肠道菌群，间接改善IBD的管理。3）硒可能会阻断结肠炎相关大肠癌中提出的一些主要的肿瘤发生途径。4）补充硒在初步临床研究中显示出令人鼓舞的结果，尤其是在缺硒患者中。尽管补充硒似乎对IBD有益，但在这方面临床研究仍处于初级阶段。需要随机临床试验来评估硒对活动性和静态IBD的短期和长期影响，尤其是在已证明有硒缺乏的IBD​​患者中。3）硒可能会阻断结肠炎相关大肠癌中提出的一些主要的肿瘤发生途径。4）补充硒在初步临床研究中显示出令人鼓舞的结果，尤其是在缺硒患者中。尽管补充硒似乎对IBD有益，但在这方面临床研究仍处于初级阶段。需要随机临床试验来评估硒对活动性和静态IBD的短期和长期影响，尤其是在已证明有硒缺乏的IBD​​患者中。3）硒可能会阻断结肠炎相关大肠癌中提出的一些主要的肿瘤发生途径。4）补充硒在初步临床研究中显示出令人鼓舞的结果，尤其是在缺硒患者中。尽管补充硒似乎对IBD有益，但在这方面临床研究仍处于初级阶段。需要随机临床试验来评估硒对活动性和静态IBD的短期和长期影响，尤其是在已证明有硒缺乏的IBD​​患者中。在这方面，临床研究仍处于初级阶段。需要随机临床试验来评估硒对活动性和静态IBD的短期和长期影响，尤其是在已证明有硒缺乏的IBD​​患者中。在这方面，临床研究仍处于初级阶段。需要随机临床试验来评估硒对活动性和静态IBD的短期和长期影响，尤其是在已证明有硒缺乏的IBD​​患者中。